|
1
|
Devaux M, Boulin M, Mounier M, Caillot D, Ahwij N, Herbin A, Bastie JN, Favennec C, Robert P, Pistre P, Bost S, Amiot P, Jacquesson L, Casasnovas O, Rossi C, Gueneau P. Clinical and Economic Impact of a Multidisciplinary Follow-Up Program in Lymphoma Patients. Cancers (Basel) 2022; 14:cancers14102532. [PMID: 35626136 PMCID: PMC9139274 DOI: 10.3390/cancers14102532] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2022] [Revised: 05/12/2022] [Accepted: 05/18/2022] [Indexed: 11/16/2022] Open
Abstract
Objectives: The UMACOACH Lymphoma is a multidisciplinary monitoring program for patients initiating a first highly haematotoxic treatment for Hodgkin or non-Hodgkin lymphoma. Patient follow-up is based on consultation with a pharmacist and planed phone calls by nurses supervised by a clinical haematologist. Our objective was to assess effectiveness and cost of the UMACOACH Lymphoma Program (ULP) and to investigate patient satisfaction and quality of life (QoL). Methods: This French monocentric case-control study included all patients enrolled in the ULP over a one-year period (cases) matched with retrospective patients receiving usual care (controls). Numbers of adverse events (AEs), re-hospitalisations, average relative dose intensity (ARDI), treatment response and survival were compared between the two groups. Among cases, patient satisfaction and QoL using the EORTC-QLQC30 questionnaire before and after treatment were evaluated. Results: Seventy-eight cases were matched to 78 controls. Twenty-six percent grade 3−4 AEs were observed in cases versus 38% in controls (p = 0.001). There were 76 and 88 re-hospitalisations in the case and control groups, respectively (p = 0.217). ARDI > 85% was observed in 92% and 82% of cases and controls, respectively (p = 0.138). No differences were observed in terms of treatment responses and survival. Estimated cost savings were of EUR 81,782 in favour of the case group. An improvement of 5.1 points was observed in the total QoL score before and after treatment in cases. Conclusions: A nurse−pharmacist−haematologist collaboration seems to be promising to reduce grade 3−4 AEs in HL and NHL patients receiving highly haematotoxic chemotherapy regimens. Cost savings from hospitalisation being avoided were also shown.
Collapse
Affiliation(s)
- Madeline Devaux
- Department of Pharmacy, University Hospital, F-21000 Dijon, France; (P.P.); (S.B.); (P.G.)
- Correspondence:
| | - Mathieu Boulin
- Department of Pharmacy, University Hospital and EPICAD LNC UMR1231, University of Burgundy & Franche Comte, F-21000 Dijon, France;
| | - Morgane Mounier
- Registre des Hémopathies Malignes de Côte d’Or, Dijon-Bourgogne University Hospital, F-21000 Dijon, France;
- INSERM, U1231, University of Burgundy & Franche Comte, UMR 1231, F-21000 Dijon, France
| | - Denis Caillot
- Department of Clinical Hematology, University Hospital INSERM UMR1231 and SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, France; (D.C.); (O.C.)
| | - Nuri Ahwij
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Adélie Herbin
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Jean Noël Bastie
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Camille Favennec
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Philippine Robert
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Pauline Pistre
- Department of Pharmacy, University Hospital, F-21000 Dijon, France; (P.P.); (S.B.); (P.G.)
| | - Stephanie Bost
- Department of Pharmacy, University Hospital, F-21000 Dijon, France; (P.P.); (S.B.); (P.G.)
| | - Pauline Amiot
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Laurence Jacquesson
- Department of Clinical Hematology, University Hospital, F-21000 Dijon, France; (N.A.); (A.H.); (J.N.B.); (C.F.); (P.R.); (P.A.); (L.J.)
| | - Olivier Casasnovas
- Department of Clinical Hematology, University Hospital INSERM UMR1231 and SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, France; (D.C.); (O.C.)
| | - Cédric Rossi
- Department of Clinical Hematology, University Hospital and SAPHIIR-UMR 1231, University of Burgundy & Franche Comte, F-21000 Dijon, France;
| | - Pauline Gueneau
- Department of Pharmacy, University Hospital, F-21000 Dijon, France; (P.P.); (S.B.); (P.G.)
| |
Collapse
|